Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein
Open Access
- 18 August 2018
- journal article
- research article
- Published by Press of International Journal of Ophthalmology (IJO Press) in International Journal of Ophthalmology
- Vol. 11 (8) , 1258-1268
Abstract
To reveal the insight mechanism of liver metastasis in uveal melanoma, we investigated cell functions of microRNA-21 in three different uveal melanoma cell lines and analyze the relationship of target gene p53 and its downstream targets. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect microRNA-21 expression in normal uveal tissue and uveal melanoma cell lines. Lenti-virus expression system was used to construct OCM-1, MuM-2B and M619 cell line with stable overexpression and inhibition of microRNA-21. In vitro cell function tests such as cell proliferation, cell apoptosis, cell circle and abilities of migration and invasion were examined by MTT, BrdU assay, flow cytometry, transwell assay and Matrigel invasion assay respectively. The target gene was predicted by bioinformatics and confirmed by using a dual luciferase reporter assay. The expression of p53 and its suspected downstream targets LIM and SH3 protein 1 (LASP1) and glutathione S transferase pi (GST-Pi) were determined by qRT-PCR in mRNA level and Western blotting analysis in protein level. Finally, the effect of microRNA-21 in a xenograft tumor model was assessed in four-week-old BALB/c nude mice. Compared to normal uveal melanoma, expressions of microRNA-21 were significantly higher in uveal melanoma cell lines. Overexpression of microRNA-21 promoted proliferation, migration, and invasion of OCM-1, M619 and MuM-2B cells, while inhibition of microRNA-21 reveal opposite effects. Wild type p53 was identified as a target gene of microRNA-21-3p, and proved by dual luciferase reporter assay. Up-regulated microRNA-21 inhibited the expression of wild type p53 gene, and the increased expression of LASP1 in mRNA level and protein level, while down-regulated microRNA-21 presented opposite way. However, GST-pi showed the potential pattern as expected, but relative mRNA level showed no statistically significant difference in OCM-1 cells. Furthermore, the mRNA expression of GST-pi was decreased in microRNA-21 overexpressing MuM-2B, and increased in M619 cells with inhibition of microRNA-21. In vivo, inhibition of microRNA-21 reduced tumor growth with statistically significant difference. These findings provide novel insight into molecular etiology of microRNA-21 in uveal melanoma cell lines, and suggest that microRNA-21 might be a potential candidate for the diagnosis and prognostic factor of human uveal melanoma.Keywords
This publication has 43 references indexed in Scilit:
- In Vivo Monitoring of Angiogenesis Inhibition via Down-Regulation of Mir-21 in a VEGFR2-Luc Murine Breast Cancer Model Using Bioluminescent ImagingPLOS ONE, 2013
- Glutathione transferase pi (GSTpi) expression in breast cancer: An immunohistochemical and molecular studyActa Histochemica, 2012
- Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinomaLaboratory Investigation, 2012
- GSTpi modulates JNK activity through a direct interaction with JNK substrate, ATF2Protein Science, 2011
- p85α mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB responseOncogene, 2010
- Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1Gut, 2010
- Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinomaScandinavian Journal of Gastroenterology, 2010
- Redefining the p53 response elementProceedings of the National Academy of Sciences, 2009
- MicroRNAs are significantly influenced by p53 and radiation in HCT116 human colon carcinoma cellsInternational Journal of Oncology, 2009
- Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study randomized trialsOphthalmology, 2004